Hasil Pencarian (1)
small molecule | CAS: 1374248-77-7
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the ac…
Kategori:
AnalgesicsAntimigraine PreparationsBCRP/ABCG2 Substrates
+23
Target Protein:
Calcitonin gene-related peptide type 1 receptor
Waktu ParuhUbrogepant has an e…
Vol. DistribusiThe apparent centra…
KlirensThe apparent oral c…
Genetik
-